All In Biotech

Drug Trial Radar · NCT03088059

Biomarker-based Study in R/M SCCHN

A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Last checked: Nov 20, 2026Latest source record: Nov 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

340

Planned (sponsor's estimate)

Start

Nov 16, 2017

Primary completion

Jun 2025

Study completion Dec 2025

Sponsor

Sponsor type
Research network
First posted
Mar 23, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a biomarker-driven trial that will enroll patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing after first-line platinum-based chemotherapy. Based on potential biomarkers and molecular alterations identified in the biopsy from the central platform, patients will be allocated in different cohorts. There will be biomarker-positive patient cohorts and immunotherapy cohorts.

Conditions

  • Carcinoma, Squamous Cell of Head and Neck

Interventions

  • AfatinibDrug

    Afatinib 40 mg given orally, once daily, 1 cycle is 28 days

  • PalbociclibDrug

    Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)

  • standard of careDrug

    Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care

  • IPH2201Drug

    protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days

  • DurvalumabDrug

    Durvalumab 1500mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days

  • NiraparibDrug

    Niraparib 300 mg given orally, once daily, 1 cycle is 28 days

  • INCAGN01876Drug

    INCAGN01876 300 mg given intravenously over 30 minutes, once every 14 days, 1 cycle is 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival Rate (PFSR) at week 16Time frame: The Progression Free Survival Rate (PFSR) analysis will be performed at week 16 for each patient in cohorts 1, 2 and 3.
  2. Objective response Rate (ORR) at week 16Time frame: Objective response Rate (ORR) at week 16 will be performed at week 16 for each patient in cohort 4.

Locations

36 sites in 5 countries. Site status is shown where the registry gives one.

  • CHU Saint-Pierre-Site Porte de Hal

    Brussels, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet

    Brussels, Belgium

  • Grand Hopital de Charleroi - Grand Hôpital de Charleroi - Site Notre Dame

    Charleroi, Belgium

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Hopital De Jolimont

    Haine-Saint-Paul, Belgium

  • AZ Groeninge Kortrijk - Campus Kennedylaan

    Kortrijk, Belgium

  • U.Z. Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • U.Z. Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • GasthuisZusters Antwerpen - Sint-Augustinus

    Wilrijk, Belgium

  • CHU Dinant Godinne - UCL Namur

    Yvoir, Belgium

  • CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre

    Bordeaux, France

  • Centre Georges-Francois-Leclerc

    Dijon, France

  • Centre Oscar Lambret

    Lille, France

  • Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau

    Nantes, France

  • Centre Antoine Lacassagne

    Nice, France

  • Institut Curie

    Paris, France

  • Institut de Cancerologie Strasbourg Europe

    Strasbourg, France

  • Institut de Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, France

  • Gustave Roussy

    Villejuif, France

  • Azienda Ospedaliero-Universitaria Careggi

    Florence, Italy

  • Azienda Ospedaliero-Universitaria Careggi

    Florence, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy

  • IRCCS - Fondazione G. Pascale

    Naples, Italy

  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

    Naples, Italy

  • ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia)

    Barcelona, Spain

  • Hospital Universitario 12 De Octubre

    Madrid, Spain

  • Hospital Clinico Universitario De Valencia

    Valencia, Spain

  • University Hospitals Birmingham NHS Foundation Trust (UHB) - UHB-Queen Elisabeth Medical Centre

    Birmingham, United Kingdom

  • NHS Lothian - Western General Hospital

    Edinburgh, United Kingdom

  • NHS Lothian - Western General Hospital

    Edinburgh, United Kingdom

  • NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital

    Glasgow, United Kingdom

  • Guy's and St Thomas' NHS - Guy s and St Thomas' NHS - Guy's Hospital

    London, United Kingdom

  • Oxford University Hospitals NHS Trust - Churchill Hospital

    Oxford, United Kingdom

  • Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.